非集中治療室病棟に入院している65歳以上の患者における市中肺炎に対するアモキシシリン単独とアモキシシリン/クラブラン酸塩の比較 (CAPTAIN)
非集中治療室病棟に入院している65歳以上の患者における市中肺炎に対するアモキシシリン単独とアモキシシリン/クラブラン酸塩の比較:非劣性ランダム化比較試験
Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions.
In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies.
Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Thus, the goal of the proposed trial is to compare clinical efficacy and safety of two CAP antimicrobial treatments, amoxicillin and amoxicillin/clavulanate, in patients aged 65 years or older and hospitalized in a non-intensive care unit (ICU) ward. The CAPTAIN study will be a multi-center, randomized, open, non-inferiority trial comparing clinical efficacy at Day 30 among patients ≥65 years of age, and hospitalized in a non-ICU ward, treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy for CAP. This will be a pivotal clinical trial that will provide evidence to inform CAP treatment guidelines.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Emmanuel MONTASSIER, Professor
- 電話番号:+33 02 53 48 20 38
- メール:emmanuel.montassier@chu-nantes.fr
研究場所
-
-
-
Angers、フランス
- 募集
- CHU Angers
-
コンタクト:
- Rafaël MAHIEU, MD
- 電話番号:+33 0241353930
- メール:rafael.mahieu@chu-angers.fr
-
Angers、フランス
- 募集
- Chu Angers
-
コンタクト:
- Delphine PLARD, MD
- 電話番号:+33 0241353637
- メール:delphine.plard@chu-angers.fr
-
Bobigny、フランス
- 募集
- CHU Avicenne AP-HP
-
コンタクト:
- Anne-Laure FERAL-PIERSSENS, MD
- 電話番号:+33 0148955555
- メール:anne-laure.feral-pierssens@aphp.fr
-
コンタクト:
- Frederic MECHAI, MD
- 電話番号:+33 0148955428
- メール:frederic.mechai@aphp.fr
-
Brest、フランス
- 募集
- CHRU Brest
-
コンタクト:
- Sylvain JAFFUEL, MD
- 電話番号:+33 0298347213
- メール:sylvain.jaffuel@chu-brest.fr
-
コンタクト:
- Rozenn LE BERRE, MD
- 電話番号:+33 029822333
- メール:rozenn.leberre@chu-brest.fr
-
La Roche-sur-Yon、フランス
- 募集
- CHD Vendée
-
コンタクト:
- Sylvaine LE GENTIL, MD
- 電話番号:+33 0251446378
- メール:sylvain.legentil@ght85.fr
-
コンタクト:
- Dominique MERRIEN, MD
- 電話番号:+33 0251446385
- メール:dominique.merrien@ght85.fr
-
La Tronche、フランス
- 募集
- CHU Grenoble-Alpes
-
コンタクト:
- Damien VIGLINO, MD
- 電話番号:+33 0476766784
- メール:DViglino@chu-grenoble.fr
-
コンタクト:
- Perrine DUMANOIR, MD
- 電話番号:+33 0476767088
- メール:PDumanoir@chu-grenoble.fr
-
Marseille、フランス
- 募集
- Assistance Publique Hopitaux De Marseille
-
コンタクト:
- Aurélie DAUMAS, MD
- 電話番号:+33 0491388719
- メール:aurelie.daumas@ap-hm.fr
-
Nantes、フランス
- 募集
- CHU de Nantes
-
主任研究者:
- Emmanuel Montassier, MD
-
コンタクト:
- Emmanuel MONTASSIER, MD
- 電話番号:+33 0253482038
- メール:emmanuel.montassier@chu-nantes.fr
-
Périgueux、フランス
- 募集
- CH Perigueux
-
コンタクト:
- Alexandrine VIDAL, MD
- 電話番号:+33 0553452525
- メール:alexandrine.vidal@ch-perigueux.fr
-
Saint-Nazaire、フランス、44600
- 募集
- CH Saint-Nazaire
-
コンタクト:
- Matthieu THIBAULT, Doctor
- 電話番号:+33 0272278174
- メール:m.thibault@ch-saintnazaire.fr
-
主任研究者:
- Matthieu THIBAULT, Doctor
-
コンタクト:
- Dorothée BOISSEAU, Doctor
- 電話番号:+33 0272278434
- メール:d.boisseau@ch-saintnazaire.fr
-
Toulouse、フランス
- 募集
- CHRU - TOULOUSE Hôpital Purpan
-
コンタクト:
- Guillaume MARTIN-BLONDEL, MD
- 電話番号:+33 0561779699
- メール:martin-blondel.g@chu-toulouse.fr
-
コンタクト:
- Frederic BALEN, MD
- 電話番号:+33 0561772579
- メール:balen.f@chu-toulouse.fr
-
Toulouse、フランス
- 募集
- CHRU TOULOUSE - Hôpital Rangueuil
-
コンタクト:
- Xavier DUBUCS, MD
- 電話番号:+33 0561775919
- メール:dubucs.x@chu-toulouse.fr
-
Vannes、フランス
- 募集
- Centre Hospitalier Bretagne Atlantique
-
コンタクト:
- Pierre BARSI, MD
- 電話番号:+33 0297014893
- メール:pierre.barsi@ch-bretagne-atlantique.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient aged 65 years or older with or without comorbidities defined by chronic diseases in immunocompetent patients,
- Patient admitted to the hospital for a CAP defined by at least two clinical signs of pneumonia (cough, sputum production, dyspnea, tachypnea, or pleuritic pain, abnormal lung auscultatory sounds, fever (temperature > 38°C) or hypothermia (<36°C)), and had radiological evidence of a new infiltrate confirming pneumonia
- Patient understanding oral and written French
- Written informed consent obtained from patient prior to participation in the study (if the patient is unable to express in writing: consent by a trusted person).
- Patients should be able to call and to answer to a phone call or to be with a relative who can help him to call or to answer questions notably raised by a medical staff belonging to the investigational site
Exclusion Criteria:
- Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency, ICU admission)
- Patient requiring ICU admission,
- Estimated Glomerular Filtration Rate < 30 ml/min,
- Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4<200/mm3),
- Exacerbation of chronic obstructive pulmonary disease,
- Life-threatening state expected to lead to possible imminent death,
- Suspected atypical bacteria requiring combined antibiotics therapy,
- Legionella suspected,
- Subjects with clinical or epidemiological environment leading to suspect a healthcare associated pneumonia with antibiotic resistant pathogen (including long-term care facility)
- Patient known to be colonized with Pseudomonas aeruginosa or Enterobacteriaceae in the respiratory tract,
- Suspicion of aspiration pneumonia,
- Administration of any antibiotic treatment for more than 24 hours before inclusion,
- History of jaundice/hepatic impairment associated with amoxicillin/clavulanate acid,
- History of bacterial pneumonia less than 1 month prior to study inclusion
- History of hypersensitivity or allergy to beta-lactam or to any excipients included in study antibiotics,
- Subject without health insurance,
- Subject without home address or difficulty in terms of follow-up (vacation, job transfer, geographical distance, lack of motivation),
- Patient under judicial protection,
- Diagnosis confirmed of SAR-Cov2 infection (PCR Test, covid antigen rapid test, chest computed tomography (CT) scan),
- Participation to another interventional study and having an exclusion period that is still in force during the screening phase or expected participation to another interventional study during participation to the CAPTAIN study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Amoxicillin
Amoxicillin is an antibiotic treatment approved in France and in many countries. The investigational medicinal products (IMPs) are: - Amoxicillin capsules : Formulated as a 500 mg capsules for PO administration (commercially available). Description in IMP file. Amoxicillin capsules contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15- 25°C. - Amoxicillin IV vials : Formulated as a 1000 mg vial for IV administration (commercially available). Description in IMP file. Amoxicillin IV vials contain compendial excipient listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C. |
Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily). Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)
他の名前:
|
|
アクティブコンパレータ:Amoxicillin/clavulanate
Amoxicillin/clavulanate is recommended by French and European guidelines for the treatment of patients aged 65 years or older, and hospitalized in a non-ICU ward, as reported above. The active comparators (IMPs) are: - Amoxicillin/clavulanate tablets: Formulated as a tablet for PO administration (commercially available). Description in IMP file. Tablets contain 500 mg of amoxicillin trihydrate and 62.5 mg of clavulanate. Amoxicillin/clavulanate tablets contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C. - Amoxicillin/clavulanate vials Vials contain 1000 mg of amoxicillin and 200 mg of clavulanate. Description in IMP file. Amoxicillin/clavulanate vials contain compendial excipients listed in the Summary Product Characteristics (SmPC), current version, and are kept in a cool dry place where the temperature stays at 15-25°C |
Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Non-inferiority
時間枠:Day 30 after inclusion (=Day 1)
|
To investigate non-inferiority in terms of clinical efficacy among patients aged 65 years or older, hospitalized in a non-ICU ward for a CAP, and treated with narrow-spectrum (amoxicillin) versus broad-spectrum (amoxicillin/clavulanate) antimicrobial therapy, at Day 30 since hospital admission. To answer this question, clinical success rate at Day 30 since admission, defined as survival after completion of antibiotic treatment course, resolution of signs and symptoms of the infection (cough, purulent sputum production, dyspnea, or pleuritic chest pain) present at baseline with no new symptoms or complications attributable to CAP and no need for further antibacterial therapy will be determined |
Day 30 after inclusion (=Day 1)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
入院期間を調べるため
時間枠:封入後30日以内(=1日目)
|
封入後30日以内(=1日目)
|
|
|
Rates of early clinical response
時間枠:Day 3 after inclusion (=Day 1)
|
Early clinical response will be defined as survival with improvement of one or more levels relative to baseline in two or more symptoms of CAP and no worsening of one or more levels in other symptoms of community-acquired bacterial pneumonia, without receipt of rescue antibacterial therapy |
Day 3 after inclusion (=Day 1)
|
|
Clinical cure after the end of treatment
時間枠:Within 30 days after inclusion (=Day 1) compared to baseline
|
The proposed endpoint of clinical cure after the end of treatment is defined as resolution in relevant signs and symptoms reported at baseline, no worsening of symptoms, and no change in antimicrobial regimen |
Within 30 days after inclusion (=Day 1) compared to baseline
|
|
To investigate total duration of antibiotic treatment, i.e., the total number of days with antibiotics during the Day 30 follow-up after hospital admission
時間枠:Day 30 after inclusion (=Day 1)
|
Days taking antibiotics from the first dose until the interruption of any antibiotic treatment during hospitalization and at late follow-up at Day 30 after hospital admission (to identify the use of any other antibiotic after hospital discharge defined as no IV, regain of autonomy identical to baseline, good clinical response and favorable evolution following initiation of antibiotics, other criteria left at the discretion of the investigators according to centers' practices) |
Day 30 after inclusion (=Day 1)
|
|
To investigate all-cause mortality at Day 30 after hospital admission
時間枠:Day 30 after inclusion (=Day 1)
|
All-cause mortality at Day 30 after hospital admission |
Day 30 after inclusion (=Day 1)
|
|
To investigate the rate of polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea
時間枠:Within 30 days after inclusion (=Day 1)
|
Number of positive polymerase chain reaction (PCR)-positive Clostridium difficile among patients with diarrhea |
Within 30 days after inclusion (=Day 1)
|
|
To investigate in-hospital mortality
時間枠:Within 30 days after inclusion (=Day 1)
|
Number of deaths during hospitalization |
Within 30 days after inclusion (=Day 1)
|
|
To investigate ICU transfer during the Day 30 follow-up
時間枠:Day 30 after inclusion (=Day 1)
|
Number of patients transferred to the ICU during the Day 30 follow-up |
Day 30 after inclusion (=Day 1)
|
|
To investigate CAP recurrence and hospital readmissions up to day 30 from hospital admission
時間枠:Day 30 after inclusion (=Day 1)
|
Number of hospital readmissions and CAP recurrence up to day 30 from hospital admission |
Day 30 after inclusion (=Day 1)
|
|
To investigate adverse events attributable to antibiotics up to day 30 from hospital admission
時間枠:Day 30 after inclusion (=Day 1)
|
Number of adverse events attributable to antibiotics and number of days with adverse events up to day 30 from hospital admission |
Day 30 after inclusion (=Day 1)
|
|
To investigate compliance with the antibiotic treatment
時間枠:Within 7 days after inclusion (=Day 1)
|
Number of days of antibiotic treatment taken |
Within 7 days after inclusion (=Day 1)
|
|
Analysis of sensitivity todiscordance
時間枠:Within 30 days after inclusion (=Day 1)
|
To investigate the agreement between the early clinical response endpoint and the investigator's clinical judgment: the agreement between early clinical response (main endpoint) and the investigator's clinical judgement (clinical success or clinical failure) will be assessed |
Within 30 days after inclusion (=Day 1)
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Frederic BALEN, Doctor、Toulouse UH
- 主任研究者:Guillaume MARTIN-BLONDEL, Doctor、Toulouse UH
- 主任研究者:Perrine DUMANOIR, Doctor、Grenoble Hospital
- 主任研究者:VIGLINO Damien, Doctor、Grenoble Hospital
- 主任研究者:Alexandrine VIDAL, Doctor、Perigueux Hospital
- 主任研究者:Delphine PLARD, Doctor、Angers UH
- 主任研究者:Rafaël MAHIEU, Doctor、Angers UH
- 主任研究者:Anne-Laure FERAL-PIERSSENS, Doctor、Avicenne AP-HP
- 主任研究者:Frederic MECHAI, Doctor、Avicenne AP-HP
- 主任研究者:Aurelie DAUMAS, Professor、Marseille Timone Hospital
- 主任研究者:Pierre BARSI, Doctor、Vannes Hospital Bretagne Atlantic
- 主任研究者:Rozenn LE BERRE, Doctor、Brest Hospital
- 主任研究者:Sylvain JAFFUEL, Doctor、Brest Hospital
- 主任研究者:Xavier DUBUCS, Doctor、Toulouse UH
- 主任研究者:Matthieu THIBAULT, Doctor、Saint-Nazaire Hospital
- 主任研究者:BOISSEAU Dorothée, Doctor、Saint-Nazaire Hospital
- 主任研究者:Dominique MERRIEN, Doctor、Centre Hospitalier Departemental Vendee
- 主任研究者:Sylvain LE GENTIL, Doctor、Centre Hospitalier Departemental Vendee
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- RC20_0015
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。